New hope for leukemia patients: drug cocktail shows promise

NCT ID NCT06773936

ENROLLING_BY_INVITATION Disease control Sponsor: SWOG Cancer Research Network Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 12, 2026 · Updated 6 times

Summary

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases of drug combinations. The main goal is to see if more patients achieve a deep molecular remission by day 85.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: asciminib, dasatinib, prednisone, blinatumomab, methotrexate, dexamethasone
What this could lead to: If successful, this could improve remission rates and offer a more effective treatment option for people with newly diagnosed Ph+ acute lymphoblastic leukemia.
What could go wrong: This is an early phase II trial with only 55 participants, so results may not apply to everyone. The drug combination may cause side effects or not work better than current treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD19+ ACUTE LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell acute lymphoblastic leukemia B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2) leukemia, acute lymphocytic, susceptibility to, 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD19+ ACUTE LEUKEMIA PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA

Contacts and locations

Locations

Baptist Memorial Health Care

Memphis, Tennessee, 38120, United States
Cleveland Clinic Foundation

Cleveland, Ohio, 44195, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Henry Ford Hospital

Detroit, Michigan, 48202, United States
Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042, United States
Rhode Island Hospital

Providence, Rhode Island, 02903, United States
UC Irvine Medical Center

Orange, California, 92868, United States
UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, 15232, United States
University of Cincinnati Cancer Ctr-UC Medical Ctr

Cincinnati, Ohio, 45267, United States
University of New Mexico Cancer Center

Albuquerque, New Mexico, 87102, United States
University of Rochester Medical Center

Rochester, New York, 14642, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.